Trial reportKnee surgery, sports traumatology, arthroscopy : official journal of the ESSKA2018
Bone marrow concentrate and platelet-rich plasma differ in cell distribution and interleukin 1 receptor antagonist protein concentration.
Trial report in Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 85 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
85 citing papers in PubMed, 1 synthesis or guideline pooled it, 215 citations in OpenAlex.
- Limited evidence in support of bone marrow aspirate concentrate as an additive to the bone marrow stimulation for osteochondral lesions of the talus: a systematic review and meta-analysis.Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA · 2023Pooled it
- Posterior iliac crest vs. proximal tibia: distinct sources of anti-inflammatory and regenerative cells with comparable 6-month clinical outcomes in treatment of osteoarthritis.Journal of translational medicine · 2024Trial
- Percutaneous bone marrow concentrate and platelet products versus exercise therapy for the treatment of rotator cuff tears: a randomized controlled, crossover trial with 2-year follow-up.BMC musculoskeletal disorders · 2024Trial
- Alveolar cleft reconstruction using bone marrow aspirate concentrate and iliac cancellous bone: A 12-month randomized clinical study.Clinical oral investigations · 2023Trial
- Bone marrow aspirate concentrate injections provide similar results versus viscosupplementation up to 24 months of follow-up in patients with symptomatic knee osteoarthritis. A randomized controlled trial.Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA · 2022Trial
- Reliable assessment of bone marrow and bone marrow concentrates using automated hematology analyzer.Regenerative medicine · 2019Trial
- Demographic Factors Affect the BMAC Proteome.Journal of proteome research · 2026Article
- Article
- Subchondral bone marrow aspirate concentrate injection improves clinical outcomes and reduces bone marrow lesions in knee osteoarthritis: 12-month retrospective analysis.Journal of orthopaedic surgery and research · 2026Article
- Growth Plate Injuries: Advances and Future Directions in Regenerative Medicine.Annals of biomedical engineering · 2026Review
- Bone Marrow Aspirate Concentrate to Treat Ankle Osteoarthritis: A Narrative Review of Progress and Challenges.Cartilage · 2025Article
- Rationale and methodology for injection therapy to treat rotator cuff disease: a scoping review.Clinics in shoulder and elbow · 2025Article
- Efficacy of intra-articular injections for the treatment of osteoarthritis: A narrative review.Osteoarthritis and cartilage open · 2025Article
- Equine bone marrow aspirate and bone marrow aspirate concentrate are enriched with interleukin-1 receptor antagonist protein.American journal of veterinary research · 2025Article
- Orthobiologics Revisited: A Concise Perspective on Regenerative Orthopedics.Current issues in molecular biology · 2025Review
- Efficacy of platelet-rich plasma use as an adjunctive treatment in autologous osteochondral transplantation for patients with osteochondral lesions of the talus accompanied by chronic lateral ankle instability.Journal of orthopaedic surgery and research · 2025Article
- Exploring the Potential of Non-Cellular Orthobiologic Products in Regenerative Therapies for Stifle Joint Diseases in Companion Animals.Animals : an open access journal from MDPI · 2025Review
- Arthroscopy combined with bone tunnel technique for treating Berndt and Harty stage III or IV osteochondral lesions of the talus.International orthopaedics · 2025Article
- Advanced Non-Operative Interventions for Anterior Knee Pain.Current reviews in musculoskeletal medicine · 2024Review
- Recent developments in Achilles tendon risk-analyzing rupture factors for enhanced injury prevention and clinical guidance: Current implications of regenerative medicine.Journal of orthopaedic translation · 2024Review
25 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
purposeBone marrow concentrate (BMC) and platelet-rich plasma (PRP) are used extensively in regenerative medicine. The aim of this study was to determine differences in the cellular composition and cytokine concentrations of BMC and PRP and to compare two commercial BMC systems in the same patient cohort.
methodsPatients (29) undergoing orthopaedic surgery were enrolled. Bone marrow aspirate (BMA) was processed to generate BMC from two commercial systems (BMC-A and BMC-B). Blood was obtained to make PRP utilizing the same system as BMC-A. Bone marrow-derived samples were cultured to measure colony-forming units, and flow cytometry was performed to assess mesenchymal stem cell (MSC) markers. Cellular concentrations were assessed for all samples. Catabolic cytokines and growth factors important for cartilage repair were measured using multiplex ELISA.
resultsColony-forming units were increased in both BMCs compared to BMA (p < 0.0001). Surface markers were consistent with MSCs. Platelet counts were not significantly different between BMC-A and PRP, but there were differences in leucocyte concentrations. TGF-β1 and PDGF were not different between BMC-A and PRP. IL-1ra concentrations were greater (p = 0.0018) in BMC-A samples (13,432 pg/mL) than in PRP (588 pg/mL). The IL-1ra/IL-1β ratio in all BMC samples was above the value reported to inhibit IL-1β.
conclusionsThe bioactive factors examined in this study have differing clinical effects on musculoskeletal tissue. Differences in the cellular and cytokine composition between PRP and BMC and between BMC systems should be taken into consideration by the clinician when choosing a biologic for therapeutic application. LEVEL OF EVIDENCE: Clinical, Level II.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.